PURE Bioscience (OTCMKTS:PURE) – Stock analysts at Zacks Investment Research lifted their FY2019 earnings estimates for shares of PURE Bioscience in a research report issued to clients and investors on Tuesday. Zacks Investment Research analyst G. Zeng now expects that the company will post earnings per share of $0.01 for the year, up from their prior estimate of ($0.01).

Separately, ValuEngine lowered PURE Bioscience from a “hold” rating to a “sell” rating in a research note on Friday, November 10th.

COPYRIGHT VIOLATION WARNING: This piece was reported by American Banking News and is the property of of American Banking News. If you are reading this piece on another domain, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/11/18/fy2019-eps-estimates-for-pure-bioscience-pure-boosted-by-zacks-investment-research.html.

Shares of PURE Bioscience (OTCMKTS:PURE) traded up $0.05 on Friday, reaching $1.05. The company’s stock had a trading volume of 10,600 shares, compared to its average volume of 35,711. PURE Bioscience has a 12-month low of $0.75 and a 12-month high of $1.36.

PURE Bioscience Company Profile

PURE Bioscience, Inc is focused on developing and commercializing antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control. The Company’s technology platform is based on stabilized ionic silver and its products contain silver dihydrogen citrate (SDC).

Receive News & Ratings for PURE Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PURE Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.